Letters sent to healthcare professionals in October 2015

In October 2015, letters were sent to healthcare professionals to provide safety information for the anticancer medicines crizotinib and vemurafenib

From:
Medicines and Healthcare products Regulatory Agency
Published
12 November 2015
Therapeutic area:
Cancer, Radiology and imaging

A letter regarding crizotinib has been sent to inform about the risk of cardiac failure.

A letter regarding vemurafenib has been sent to inform about the risk of potentiation of radiation toxicity.

Article citation: Drug Safety Update Vol 9 issue 4, November 2015: 3.

Updates to this page

Published 12 November 2015